Table 1.
Isolate type | Pre-vaccine period (n=424)a | Post-vaccine period (n=149)b | Total period (n=573) | |||
---|---|---|---|---|---|---|
No. cases (%)c | Incidenced | No. cases (%) | Incidenced | No. cases (%)c | Incidenced | |
Type b | 416 (98) | 2.45 | 114 (77) | 0.24 | 530 (92) | 0.90 |
Non-type b | 8 (2) | 0.04 | 35 (23) | 0.07 | 43 (8) | 0.06 |
Type a | 5 (1) | 0.02 | 23 (15) | 0.05 | 28 (5) | 0.04 |
Type e | 0 (0) | 0.00 | 3 (2) | 0.01 | 3 (1) | 0.00 |
Type f | 1 (0) | 0.00 | 2 (1) | 0.01 | 3 (1) | 0.00 |
Non-capsulated | 2 (0) | 0.02 | 7 (5) | 0.01 | 9 (2) | 0.01 |
NOTE. The Hib conjugate vaccine was introduced in the childhood immunization program in August 9, 1999.
From March 9, 1996 to August 8, 1999.
From August 9, 1999 to September 9, 2007.
Sum of percents are not equal to 100% due to rounding.
Mean annual cumulative incidence (per 100,000 population) was calculated for the cases of H. influenzae type b (365), type a (16), type e (2), type f (2) and non-capsulated (4) which resided within Metropolitan Salvador.